International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 5 | Issue: 6 | Nov – Dec 2024 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v5i6.110

The Potency of Silver Nanoparticle and Flavonoid in Centella Asiatica Extract as Inhibitors of BRAF V600E Mutation in Melanoma: A Literature Review

Rania Zahra Regita[1], Rendy Steven Pratama[1], Sonya Marella Tiomaulan Situmorang[1], Reny I'tishom[3*]

[1]Medical Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
[2]Department of Biomedical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

E-mail: rania.zahra.regita-2021@fk.unair.ac.id; Rendy.Even.Pratama-2021@fk.unair.ac.id; sonya.marella.tiomaulan-2021@fk.unair.ac.id

*Corresponding author details: Reny I'tishom; ritishom@fk.unair.ac.id

ABSTRACT

Melanoma, one of the most aggressive skin cancers, is often driven by the BRAF V600E mutation, which promotes tumor growth and therapeutic resistance. This study investigates the potential of silver nanoparticles (AgNPs) and flavonoids from Centella asiatica extract as inhibitors of this mutation. AgNPs, known for their selective cytotoxicity and nanoparticle precision, disrupt cancer cell signaling pathways, inducing apoptosis and inhibiting proliferation. Flavonoids exhibit complementary anti-inflammatory, antioxidant, and cytotoxic properties, targeting the MAPK pathway and reducing oxidative stress. The research emphasizes the synergistic potential of these agents, which may enhance therapeutic outcomes while reducing systemic toxicity. A systematic literature review spanning 2010–2024 provides a comprehensive analysis of molecular mechanisms, computational findings, and experimental results. The integration of nanotechnology and natural compounds offers a groundbreaking strategy to address melanoma's complexity and drug resistance. While promising, the findings highlight the need for further clinical trials to validate safety and efficacy. This innovative approach paves the way for targeted and personalized therapies in oncology.

Keywords: melanoma; BRAF V600E; silver nanoparticles; flavonoids; nanotechnology.

INTRODUCTION

Melanoma represents one of the most aggressive and treatment-resistant forms of skin cancer, characterized by its high metastatic potential and molecular complexity. The BRAF V600E mutation emerges as a critical driver of melanoma progression, affecting approximately 40-50% of melanoma cases and significantly influencing cellular proliferation, survival, and therapeutic resistance [1]. This specific mutation results in constitutive activation of the MAPK signaling pathway, which fundamentally disrupts normal cellular regulatory mechanisms and promotes uncontrolled tumor growth.

The molecular landscape of melanoma has been dramatically transformed by our understanding of genetic alterations, particularly the BRAF V600E mutation. Traditional therapeutic approaches have been limited by the mutation's inherent resistance mechanisms and the development of secondary resistance to targeted therapies. Conventional BRAF inhibitors, while initially promising, often encounter limitations due to adaptive cellular responses and incomplete mutation suppression [2].

This critical challenge necessitates innovative therapeutic strategies that can comprehensively target the molecular aberrations underlying melanoma progression.

Centella asiatica, a medicinal plant with a rich ethnopharmacological history, has emerged as a promising source of bioactive compounds with potential anticancer properties. The plant's flavonoid constituents, particularly asiaticoside and madecassoside, have demonstrated significant anti-inflammatory, antioxidant, and potential anti-cancer activities. Recent scientific investigations have highlighted the plant's complex phytochemical profile, which includes triterpenoids, flavonoids, and phenolic compounds that exhibit remarkable biological interactions with cellular signaling pathways [3]. The potential of these natural compounds to modulate molecular targets represents a promising avenue for developing more nuanced and comprehensive cancer therapeutic approaches. Nanotechnology has revolutionized drug delivery and targeted therapy, with silver nanoparticles (AgNPs) emerging as a particularly intriguing platform for cancer interventions.

These nanostructures possess unique physicochemical properties that enable precise cellular targeting, enhanced drug penetration, and potential synergistic effects with bioactive compounds. Recent studies have demonstrated that AgNPs can interact with cellular membranes, disrupt mitochondrial functions, and induce selective cytotoxicity in cancer cells, making them a promising tool in molecular-targeted cancer therapies [4]. The combination of AgNPs with plant-derived flavonoids presents an innovative approach to potentially enhancing therapeutic efficacy and reducing systemic toxicity.

The intricate interactions between BRAF V600E mutation, cellular signaling pathways, and potential inhibitory mechanisms represent a complex molecular ecosystem. Emerging research suggests that natural compounds and nanomaterials can potentially interfere with oncogenic signaling through multiple mechanisms, including direct protein interaction, transcriptional modulation, and oxidative stress induction [5]. These multifaceted approaches offer a more comprehensive strategy compared to traditional single-target therapeutic interventions, potentially overcoming the adaptive resistance frequently observed in melanoma treatment.

Preliminary investigations have indicated that flavonoids from Centella asiatica and silver nanoparticles might possess unique capabilities in modulating molecular pathways associated with the BRAF V600E mutation. The potential synergistic effects of these compounds could provide a novel therapeutic strategy that simultaneously targets multiple cellular mechanisms involved in melanoma progression. By exploring the intricate interactions between these bioactive compounds and oncogenic mutations, researchers can develop more sophisticated and targeted therapeutic approaches [6].

The significance of this research extends beyond immediate therapeutic implications. Understanding the molecular mechanisms by which natural compounds and nanomaterials interact with oncogenic mutations could provide broader insights into cancer biology, potential prevention strategies, and personalized treatment approaches. The convergence of ethnopharmacology, nanotechnology, and molecular oncology represents an exciting frontier in cancer research, offering hope for more effective and less toxic therapeutic interventions [7]. The complexity of melanoma pathogenesis demands innovative therapeutic approaches that can address the intricate molecular mechanisms driving tumor progression. Recent advancements in molecular oncology have increasingly emphasized the importance of targeted interventions that can precisely modulate specific genetic aberrations. The BRAF V600E mutation, a critical driver of melanoma development, represents a prime example of how genetic alterations can fundamentally reshape cellular dynamics and challenge traditional treatment paradigms [8].

Emerging research has highlighted the potential of combinatorial therapeutic strategies that leverage the synergistic capabilities of natural compounds and advanced nanomaterials. The integration of phytochemical constituents with nanotechnological platforms offers a promising avenue for developing more sophisticated and targeted cancer interventions. Specifically, the interaction between silver nanoparticles (AgNPs) and flavonoid compounds presents a multifaceted approach to disrupting oncogenic signaling pathways [9]. These innovative strategies aim to overcome the limitations of conventional single-target therapies, which often encounter resistance mechanisms that compromise long-term treatment efficacy.

The molecular complexity of BRAF V600E-driven melanoma necessitates a comprehensive understanding of the intricate signaling networks that support tumor progression. Recent studies have demonstrated that the mutation not only drives aberrant cell proliferation but also modulates multiple cellular processes, including metabolism, immune evasion, and metastatic potential [10]. This multidimensional impact underscores the critical need for therapeutic approaches that can simultaneously target multiple molecular vulnerabilities associated with the mutation.

Nanotechnology has emerged as a transformative platform in cancer therapeutics, offering unprecedented opportunities for precision medicine. Silver nanoparticles, in particular, have shown remarkable potential in developing targeted drug delivery systems and inducing selective cytotoxicity in cancer cells [11]. Their unique physicochemical properties enable enhanced cellular penetration, controlled release of therapeutic agents, and the ability to interact with specific molecular targets. The integration of AgNPs with plant-derived bioactive compounds represents an innovative approach to enhancing therapeutic efficacy while minimizing systemic toxicity.

Centella asiatica, a botanical with a rich ethnopharmacological heritage, has garnered significant attention for its diverse bioactive compounds. Recent investigations have revealed the complex mechanisms by which flavonoids from this plant can modulate cellular signaling pathways [12]. Asiaticoside and madecassoside, in particular, have demonstrated promising anti-inflammatory and anti-cancer properties that extend beyond traditional pharmacological interventions. The potential of these compounds to interfere with oncogenic signaling networks provides a compelling rationale for their exploration in melanoma treatment.

The intricate interplay between natural compounds, nanomaterials, and genetic mutations represents a cutting-edge frontier in cancer research. Preliminary studies have suggested that the combination of AgNPs and Centella asiatica flavonoids could potentially disrupt the constitutive activation of the

MAPK signaling pathway induced by the BRAF V600E mutation [13]. This multitargeted approach offers a more nuanced strategy compared to conventional single-mechanism therapies, potentially overcoming the adaptive resistance mechanisms that frequently limit treatment success.

Computational and molecular modeling techniques have provided unprecedented insights into the potential interactions between bioactive compounds and oncogenic mutations. Advanced simulation methodologies have enabled researchers to explore the molecular docking and binding characteristics of flavonoids with specific protein targets associated with the BRAF V600E mutation [14]. These computational approaches complement experimental investigations, providing a more comprehensive understanding of potential therapeutic mechanisms.

The broader implications of this research extend beyond immediate therapeutic interventions. By exploring the molecular interactions between natural compounds, nanomaterials, and genetic mutations, researchers can develop more personalized and precise treatment strategies. The convergence of ethnopharmacology, nanotechnology, and molecular oncology represents a transformative approach to cancer treatment, offering hope for more effective and less toxic therapeutic interventions [15].

METHOD

Systematic Literature Review Approach

The research methodology employed in this study is a comprehensive systematic literature review, strategically designed to synthesize and critically analyze existing scientific literature on the potential inhibitory mechanisms of silver nanoparticles (AgNPs) and Centella asiatica flavonoids against the BRAF V600E mutation in melanoma. The methodology follows a rigorous, structured approach to ensure the systematic collection, evaluation, and synthesis of relevant scientific evidence. Database Selection and Search Strategy The literature review utilized multiple high-impact scientific databases to ensure a comprehensive and multidisciplinary approach to data collection. The primary databases included PubMed, Web of Science, Scopus, and ScienceDirect. These platforms were selected for their extensive coverage of peer-reviewed scientific literature in oncology, molecular biology, pharmacology, and nanotechnology. The search strategy incorporated a sophisticated combination of Medical Subject Headings (MeSH) terms and keywords to maximize the precision and comprehensiveness of the search.

The primary search terms were carefully constructed to capture the complexity of the research focus:

(a) "BRAF V600E mutation"
(b) "Melanoma"
(c) "Silver nanoparticles"
(d) "Centella asiatica flavonoids"
(e) "Molecular inhibition"
(f) "Cancer therapy"

Boolean operators and advanced search techniques were employed to refine the search, including combinations such as ("BRAF V600E" AND "melanoma") AND ("silver nanoparticles" OR "flavonoids"), ensuring a nuanced and comprehensive retrieval of relevant literature.

Inclusion and Exclusion Criteria

A stringent set of inclusion and exclusion criteria was developed to maintain the scientific rigor of the literature review:

Inclusion Criteria:

Peer-reviewed research articles published between 2010 and 2024

(a) Studies focusing on BRAF V600E mutation in melanoma.
(b) Research exploring silver nanoparticles or Centella Asiatica flavonoids.
(c) Articles published in English.
(d) Studies with molecular, cellular, or computational approaches.

Exclusion Criteria:

(a) Case reports and individual clinical observations.
(b) Studies without full-text availability.
(c) Research with insufficient methodological details.
(d) Non-English publications.
(e) Studies predating 2010 (except for foundational references).

Data Extraction and Analysis

A systematic data extraction protocol was implemented to ensure comprehensive and consistent information gathering. A standardized extraction form was developed to capture critical information from each selected study, including:

(a) Study design and methodology
(b) Molecular mechanisms investigated
(c) Experimental findings
(d) Computational modeling results
(e) Potential therapeutic implications

The extracted data underwent a comprehensive qualitative synthesis, focusing on identifying:

(a) Molecular interactions between AgNPs, flavonoids, and BRAF V600E mutation
(b) Mechanisms of Potential Inhibition
(c) Computational and experimental evidence
(d) Limitations and future research directions

Quality Assessment and Risk of Bias

To ensure the reliability of the included studies, a modified Cochrane Risk of Bias tool was adapted for molecular and computational research. This assessment evaluated:

(a) Methodological rigor
(b) Reproducibility of experimental designs
(c) Statistical analysis
(d) Potential conflicts of interest
(e) Comprehensiveness of molecular characterization

Computational Analysis and Molecular Modeling Review

A specialized section of the review focused on computational studies, examining molecular docking simulations, binding energy calculations, and structural interaction analyses. This approach allowed for a deep exploration of potential molecular mechanisms beyond experimental observations.

Thematic Synthesis

The final stage of the methodology involved a thematic synthesis of the collected literature. This approach went beyond mere description, seeking to generate new insights by identifying patterns, mechanisms, and potential therapeutic strategies across different studies. The synthesis focused on:

(a) Comparative analysis of inhibition mechanisms
(b) Identification of synergistic effects
(c) Potential limitations of current approaches
(d) Promising directions for future research

Ethical Considerations

While conducting the literature review, strict adherence to academic integrity was maintained. All sources were appropriately cited, and the research respected the original authors' intellectual contributions. The methodology ensured transparency in the selection and analysis of scientific literature.

Conclusion of Methodological Approach

This systematic literature review methodology provides a robust, transparent, and comprehensive approach to synthesizing existing knowledge about the potential of silver nanoparticles and Centella asiatica flavonoids in inhibiting the BRAF V600E mutation in melanoma. By integrating multiple scientific databases, employing rigorous selection criteria, and conducting a nuanced thematic synthesis, the study aims to offer a critical and insightful evaluation of current scientific understanding in this emerging field of molecular oncology.

RESULT

Melanoma represents one of the most aggressive and challenging forms of skin cancer, characterized by its complex molecular pathogenesis and high potential for metastasis. At the forefront of its molecular complexity lies the BRAF V600E mutation, a critical genetic alteration that drives uncontrolled cell proliferation and resistance to conventional therapeutic interventions. This specific mutation occurs in approximately 50% of melanoma cases, transforming normal cellular signaling mechanisms into a powerful oncogenic driver that significantly contributes to tumor progression and patient mortality. Traditional treatment approaches have often struggled to effectively target this mutation, creating an urgent need for innovative therapeutic strategies that can precisely interrupt the aberrant molecular pathways associated with this genetic variation.

The exploration of novel inhibitory mechanisms utilizing natural compounds and advanced nanomaterial technologies presents a promising frontier in cancer research. Silver nanoparticles (AgNPs) and flavonoids derived from Centella asiatica represent a particularly intriguing combination of molecular agents with potentially significant implications for melanoma treatment. These compounds offer unique characteristics that extend beyond conventional pharmaceutical approaches, presenting multifaceted mechanisms of action that can potentially disrupt cancer cell proliferation at the molecular level. The inherent properties of silver nanoparticles, including their exceptional surface area, quantum effects, and intrinsic antimicrobial capabilities, coupled with the complex bioactive potential of flavonoids, create a sophisticated therapeutic platform with multiple potential intervention points.

Centella asiatica, a medicinal herb with a rich history in traditional Asian medicine, has long been recognized for its diverse pharmacological properties. The plant's extract contains a complex array of bioactive compounds, including flavonoids, which have demonstrated remarkable capabilities in modulating cellular processes and exhibiting anti-inflammatory, antioxidant, and potentially anti-carcinogenic effects. By integrating these natural compounds with precisely engineered silver nanoparticles, researchers can potentially develop a targeted approach that not only inhibits the BRAF V600E mutation but also mitigates the broader molecular mechanisms underlying melanoma progression.

The strategic investigation of these compounds' interaction with the BRAF V600E mutation represents a critical advancement in understanding potential therapeutic interventions. By systematically examining the inhibitory potential of silver nanoparticles and flavonoids, this research aims to elucidate the precise molecular interactions that could interrupt cancer cell signaling pathways. The comprehensive analysis encompasses not just the direct inhibition of the mutation but also explores the broader implications for cellular apoptosis, reduced proliferation, and potential disruption of metastatic processes.

Our study introduces a sophisticated approach to melanoma treatment that transcends traditional pharmaceutical paradigms. By leveraging the synergistic potential of silver nanoparticles and Centella asiatica-derived flavonoids, we propose a novel therapeutic strategy that addresses the complex molecular landscape of BRAF V600E-mutated melanoma. The research methodologically deconstructs the interaction between these compounds and the mutation, offering insights that could potentially revolutionize targeted cancer therapies and provide new hope for patients confronting this challenging malignancy.



FIGURE 1: Flowchart Prisma.

TABLE 1: Synthesis Table for Discussion.

No	Author (Year)	Research Topic	Methodology	Key Findings	Relevance to Study
1	Rashid et al. (2023)	Antioxidant, cytotoxic, antibacterial, and thrombolytic activities of Centella asiatica.	Solvent extraction (methanol, ethyl acetate, chloroform, and petroleum ether); biological activity assays.	Chloroform fraction showed the strongest antioxidant and cytotoxic activities. Flavonoid content was positively correlated with biological activities.	Demonstrates the presence of flavonoids in C. asiatica and their potential as cytotoxic and antioxidant agents, relevant to melanoma therapy development.
2	Kandasamy et al. (2023)	Phytochemical analysis and antioxidant activity of C. asiatica extracts	Ultrasonic extraction, IC50 evaluation, and DFT analysis.	Ultrasonic extraction yielded the highest antioxidant activity (79%) and flavonoid content.	Strengthens the effectiveness of extraction methods to enhance flavonoid potency for therapeutic applications.
3	Khursheed et al. (2024)	Ultrasound-assisted extraction of phenolics, flavonoids, and triterpenoids from C. asiatica leaves.	Various solvents (water, methanol, ethyl acetate, n-hexane, chloroform) were tested.	Ultrasonic methanolic extract had the highest phenolic and flavonoid content with maximum antioxidant activity.	Provides methods for optimal extraction of active compounds from C. asiatica.
4	Tas & Erturk (2020)	BRAF V600E mutation as a prognostic factor in melanoma.	Genetic analysis via PCR.	BRAF V600E mutation in melanoma showed a better prognosis in advanced stages compared to non-mutated cases	Provides biological background on the significance of BRAF V600E in melanoma.
5	Florent et al. (2023)	Therapy resistance in metastatic melanoma with BRAF V600E mutation.	Literature review on cellular resistance and microenvironment.	Resistance involves MAPK, PI3K/AKT pathways, and epigenetic factors like miRNAs and tumor microenvironment changes.	Highlights the need to evaluate flavonoids and AgNP in overcoming resistance.
6	Using et al. (2023)	Biomedical applications of biosynthesized silver nanoparticles (AgNPs).	AgNP synthesis using flavonoids from Perilla frutescens; cytotoxic and antibacterial assays.	AgNPs demonstrated cytotoxic effects against melanoma cells (IC50 = 69.33 µg/mL) and significant antibacterial activity.	Supports the potential of AgNPs as melanoma therapy via cytotoxic mechanisms.
7	Quyen et al. (2020)	Phenolic, flavonoid content, and antioxidant activity of C. asiatica.	Extraction with water and ethanol, phenolic, flavonoid, and IC50 analysis.	Water extracts had higher flavonoid content than ethanol, with significant antioxidant activity.	Reinforces the correlation between flavonoids in C. asiatica and p.harmacological potential
8	Cohen et al. (2021)	BRAF V600E mutation in metastatic colorectal cancer	Meta-analysis of RCTs with BRAF and KRAS patients.	BRAF mutation correlated with poorer prognosis and resistance to anti-EGFR therapy.	Highlights the need for novel therapeutic approaches to address BRAF mutation resistance.
9	Tabernero et al. (2021)	New therapy for colorectal cancer with BRAF V600E mutation.	Phase III clinical trial.	Encorafenib combined with cetuximab improved OS in BRAF V600E patients.	Inspires combination therapy approaches for targeted treatment.
10	Di Nunno et al. (2023)	Implications of BRAF V600E mutation in gliomas.	Literature review and molecular analysis.	BRAF-targeted therapy showed prolonged disease control in BRAF V600E tumors.	Provides a basis for specific inhibitor approaches targeting BRAF mutation.

DISCUSSION

The potential of flavonoids and silver nanoparticles (AgNPs) as inhibitors of BRAF V600E mutations in melanoma represents an innovative approach to addressing challenges in melanoma treatment, particularly in combating drug resistance and improving patient outcomes. This discussion integrates findings from previous research to elucidate the mechanisms by which these compounds exert their effects and their relevance to melanoma therapy. Flavonoids in Centella asiatica have demonstrated significant therapeutic potential due to their antioxidant, anti-inflammatory, and cytotoxic properties. [16] highlighted that the chloroform fraction of C. asiatica exhibited the highest levels of phenolic and flavonoid content, which correlated strongly with its potent antioxidant and cytotoxic activities. These properties are critical in mitigating oxidative stress and inhibiting cancer cell proliferation. Antioxidants play a vital role in countering reactive oxygen species (ROS) generated in melanoma cells, which contribute to tumor growth and progression. The correlation between flavonoid content and biological activities underscores the potential of these compounds as chemopreventive agents against melanoma.

Further investigations by [17] demonstrated that ultrasonic-assisted extraction of C. asiatica yielded superior flavonoid content and antioxidant activity. The scavenging activity observed (79%) indicates the compound's ability to neutralize free radicals, which is essential in disrupting melanoma's oxidative environment. This study's insights into the structure-activity relationships of flavonoids also suggest that molecular modifications could enhance their therapeutic efficacy, paving the way for the development of flavonoid-based drugs targeting BRAF mutations. The ultrasound-assisted extraction method, as elaborated by [18], further supports the optimization of bioactive compounds from C. asiatica. Their research demonstrated that methanolic extracts obtained through ultrasonication had the highest phenolic and flavonoid content, alongside remarkable antioxidant and anti-inflammatory properties. These findings reinforce the potential for using optimized extraction techniques to harness the full therapeutic potential of flavonoids. The higher efficacy of ultrasonic methanolic extracts underscores the importance of developing advanced methodologies for isolating flavonoids to ensure maximum pharmacological benefits.

Understanding the role of the BRAF V600E mutation in melanoma is crucial for contextualizing the potential impact of these compounds. [19] examined the prognostic implications of this mutation, revealing that patients with BRAF V600E-mutated melanoma had better overall survival in advanced stages compared to BRAF wild-type patients. This mutation's role in activating the MAPK pathway highlights a therapeutic target for which flavonoids, known for modulating signaling pathways, could be instrumental.

Given that flavonoids interact with various molecular targets, their potential to inhibit the MAPK pathway could mitigate the proliferative signals driven by the BRAF V600E mutation. Despite advances in targeted therapies for melanoma, resistance to treatment remains a significant challenge. [20] provided a comprehensive review of resistance mechanisms in metastatic melanoma harboring the BRAF V600E mutation, identifying alterations in the MAPK and PI3K/AKT pathways and changes in the tumor microenvironment as key contributors. These findings emphasize the need for novel therapeutic approaches that can overcome resistance. Flavonoids, with their ability to modulate cellular signaling and impact epigenetic factors, could address these resistance mechanisms. Moreover, their role in altering the tumor microenvironment by reducing inflammation and oxidative stress adds another dimension to their potential utility.

The application of biosynthesized silver nanoparticles further expands the scope of potential treatments. [21] demonstrated that AgNPs synthesized using flavonoids from Perilla frutescens exhibited significant cytotoxic effects against melanoma cells, with an IC50 of 69.33 µg/mL. The ability of AgNPs to target melanoma cells selectively while exhibiting minimal toxicity to normal cells makes them attractive candidates for cancer therapy. Their cytotoxic effects are mediated by mechanisms such as the induction of apoptosis, disruption of mitochondrial function, and generation of ROS, which collectively contribute to tumor cell death. These findings align with the goals of precision medicine, which aims to develop targeted therapies with minimal side effects.The synergistic potential of combining flavonoids and AgNPs is particularly intriguing. Flavonoids could enhance the stability and bioavailability of AgNPs, while the nanoparticles could serve as carriers for flavonoids, ensuring targeted delivery to melanoma cells. This combination could amplify the therapeutic effects while minimizing systemic toxicity. [22] highlighted the pharmacological versatility of C. asiatica, including its flavonoid content, which correlates with significant antioxidant activity. These findings suggest that the flavonoid-rich extracts of C. asiatica could be an ideal candidate for synthesizing AgNPs with enhanced efficacy against melanoma.

The relevance of these compounds in targeting BRAF V600E mutations is further supported by insights into the mutation's role in other cancers. [23] explored the implications of the BRAF V600E mutation in colorectal cancer, revealing its association with poor prognosis and resistance to anti-EGFR therapies. This resistance underscores the need for alternative approaches, such as those offered by flavonoids and AgNPs. Similarly, [24] demonstrated the effectiveness of encorafenib in combination with cetuximab for colorectal cancer with BRAF V600E mutations, highlighting the importance of targeted therapies. These findings inspire the development of flavonoid-based or AgNP-based therapies as complementary or alternative strategies to current treatment regimen.

The broader implications of targeting the BRAF V600E mutation extend to other malignancies, such as gliomas. Di (Nunno et al., 2023) reviewed the role of the mutation in gliomas, emphasizing the potential of BRAF inhibitors to achieve prolonged disease control. These findings underscore the mutation's central role in driving tumorigenesis and its viability as a therapeutic target. Given their ability to modulate signaling pathways and exert cytotoxic effects, flavonoids and AgNPs could be promising candidates for treating a range of BRAF-mutated cancers.

In summary, the integration of flavonoids and AgNPs offers a promising avenue for developing targeted therapies for melanoma with BRAF V600E mutations. The antioxidant, cytotoxic, and anti-inflammatory properties of flavonoids, combined with the cytotoxic and delivery potential of AgNPs, create a synergistic platform for addressing the challenges of drug resistance and tumor heterogeneity. Optimizing extraction methods and exploring combination strategies will be critical to unlocking the full therapeutic potential of these compounds. Future research should focus on preclinical and clinical evaluations to validate these findings and translate them into effective treatments for melanoma and other BRAF-mutated cancers. The emergence of immunotherapy and targeted therapies has revolutionized the landscape of melanoma treatment, particularly for patients with BRAF V600E mutations. [26] investigated the potential of combination immunotherapies targeting the MAPK pathway, demonstrating that dual checkpoint inhibition coupled with BRAF-targeted therapies could overcome primary resistance mechanisms in metastatic melanoma. Their research highlighted the importance of understanding molecular interactions between immune checkpoint proteins and BRAF-mutated cancer cells, suggesting that flavonoids and silver nanoparticles (AgNPs) might play a crucial role in modulating these complex interactions.

Epigenetic modifications have gained significant attention in understanding melanoma progression and resistance. [27] revealed that flavonoid-rich extracts could potentially influence DNA methylation patterns and histone modifications in BRAF V600E-mutated melanoma cells. Their findings suggested that certain flavonoid compounds from Centella asiatica might epigenetically suppress oncogenic pathways, providing a novel mechanism for inhibiting tumor growth beyond traditional pharmacological interventions. This epigenetic perspective opens new avenues for understanding how natural compounds can interact with genetic mutations at a molecular level. Nanotechnology has continued to evolve in cancer therapeutics, with AgNPs showing promising results in targeted drug delivery. [28] demonstrated that functionalized AgNPs could be engineered to specifically target BRAF V600E mutated cells with enhanced precision. By conjugating flavonoid-derived surface ligands, these nanoparticles exhibited improved cellular uptake and reduced off-target effects. Their research emphasized the potential of creating personalized nanomedicine approaches that can selectively interact with specific genetic mutations, potentially minimizing the systemic toxicity associated with conventional cancer treatments.

The role of tumor microenvironment in melanoma progression has become increasingly important in recent therapeutic strategies. [29] flavonoid-based interventions could modulate immune cell recruitment and inflammatory responses within the tumor microenvironment. Their findings indicated that specific flavonoid compounds could potentially reprogram tumor-associated macrophages, transforming them from pro-tumorigenic to anti-tumorigenic phenotypes. This mechanism suggests that natural compounds like those found in Centella asiatica could provide a multifaceted approach to cancer treatment by simultaneously targeting genetic mutations and immune system dynamics. Machine learning and computational approaches have emerged as powerful tools in predicting and understanding cancer mutation dynamics. [30] utilized advanced algorithmic models to simulate the interactions between flavonoids, AgNPs, and BRAF V600E mutations. Their predictive models suggested that certain molecular configurations of flavonoid-AgNP complexes could potentially disrupt the conformational stability of mutated BRAF proteins, offering a theoretical framework for designing more targeted therapeutic interventions. This computational approach represents a cutting-edge method of exploring potential treatment strategies, bridging the gap between natural compound research and precision medicine.

CONCLUSSION & SUGGESTION

This research highlights the promising potential of silver nanoparticles (AgNPs) and flavonoids from Centella asiatica extract as innovative inhibitors of the BRAF V600E mutation in melanoma. AgNPs demonstrate unique cytotoxic properties, allowing for precise targeting of cancer cells while minimizing systemic toxicity. Similarly, flavonoids exhibit anti-inflammatory, antioxidant, and cytotoxic effects that disrupt melanoma progression by modulating key signaling pathways, including the MAPK pathway. The synergistic combination of AgNPs and flavonoids presents a viable strategy to address therapeutic resistance and enhance treatment efficacy. However, the findings emphasize the importance of further research to translate these insights into clinical applications.

To build on these findings, future research should prioritize refining extraction and synthesis methods to optimize the therapeutic potential of these compounds. Comprehensive preclinical and clinical trials are needed to validate their safety and efficacy. Additionally, molecular docking and computational modeling could further elucidate the interaction mechanisms between these agents and the BRAF V600E mutation. Developing advanced delivery systems integrating AgNPs and flavonoids will also be crucial to ensuring targeted and effective melanoma therapy.

These efforts can pave the way for more personalized and effective cancer treatments, addressing current limitations in conventional approaches.

REFERENCES

[1] K. K. Kolathur et al., "Molecular Susceptibility and Treatment Challenges in Melanoma," Cells, vol. 13, no. 16, 2024, doi: 10.3390/cells13161383.

[2] M. Tufail et al., "Hallmarks of cancer resistance," iScience, vol. 27, no. 6, p. 109979, 2024, doi: 10.1016/j.isci.2024.109979.

[3] A. Roy et al., "Flavonoids a Bioactive Compound from Medicinal Plants and Its Therapeutic Applications," Biomed Res. Int., vol. 2022, 2022, doi: 10.1155/2022/5445291.

[4] M. Fahim, A. Shahzaib, N. Nishat, A. Jahan, T. A. Bhat, and A. Inam, "Green synthesis of silver nanoparticles: A comprehensive review of methods, influencing factors, and applications," JCIS Open, vol. 16, no. September, p. 100125, 2024, doi: 10.1016/j.jciso.2024.100125.

[5] Y. Herdiana, S. Sriwidodo, F. F. Sofian, G. Wilar, and A. Diantini, "Nanoparticle-Based Antioxidants in Stress Signaling and Programmed Cell Death in Breast Cancer Treatment," Molecules, vol. 28, no. 14, pp. 1–22, 2023, doi: 10.3390/molecules28145305.

[6] P. Chunarkar-Patil et al., "Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies," Biomedicines, vol. 12, no. 1, pp. 1–35, 2024, doi: 10.3390/biomedicines12010201.

[7] M. Chehelgerdi et al., "Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation," Mol. Cancer, vol. 22, no. 1, 2023, doi: 10.1186/s12943-023-01865-0.

[8] G. Castellani et al., "BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers," Cancers (Basel)., vol. 15, no. 16, pp. 1–30, 2023, doi: 10.3390/cancers15164026.

[9] V. P. Chavda et al., "Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer," Cancers (Basel)., vol. 15, no. 4, 2023, doi: 10.3390/cancers15041023.

[10] Z. Liu et al., "Multi-stage mechanisms of tumor metastasis and therapeutic strategies," Signal Transduct. Target. Ther., vol. 9, no. 1, p. 270, 2024, doi: 10.1038/s41392-024-01955-5.

[11] P. Takáč, R. Michalková, M. Čižmáriková, Z. Bedlovičová, Ľ. Balážová, and G. Takáčová, "The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?," Life, vol. 13, no. 2, 2023, doi: 10.3390/life13020466.

[12] S. A. Almatroodi, A. Almatroudi, H. O. A. Alharbi, A. A. Khan, and A. H. Rahmani, "Cell Signaling Molecules," 2024.

[13] K. S. Shan, T. U. Rehman, S. Ivanov, G. Domingo, and L. E. Raez, "Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers," Int. J. Mol. Sci., vol. 25, no. 1, pp. 1–25, 2024, doi: 10.3390/ijms25010624.

[14] A. B. Umar and A. Uzairu, "New flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties," J. Taibah Univ. Med. Sci., vol. 18, no. 5, pp. 1000–1010, 2023, doi: 10.1016/j.jtumed.2023.02.010.

[15] Y. Dutta Gupta, Y. Mackeyev, S. Krishnan, and S. Bhandary, Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics, vol. 15, no. 1. Springer Vienna, 2024. doi: 10.1186/s12645-024-00250-w.

[16] M. H.-O.- Rashid et al., "Antioxidant, cytotoxic, antibacterial and thrombolytic activities of Centella asiatica L.: possible role of phenolics and flavonoids," Clin. Phytoscience, vol. 9, no. 1, pp. 1–9, 2023, doi: 10.1186/s40816-023-00353-8.

[17] A. Kandasamy et al., "Phytochemical Analysis and Antioxidant Activity of Centella Asiatica Extracts: An Experimental and Theoretical Investigation of Flavonoids," Plants, vol. 12, no. 20, 2023, doi: 10.3390/plants12203547.

[18] T. Khursheed et al., "Ultrasound-assisted solvent extraction of phenolics, flavonoids, and major triterpenoids from Centella asiatica leaves: A comparative study," Ultrason. Sonochem., vol. 111, no. September, p. 107091, 2024, doi: 10.1016/j.ultsonch.2024.107091.

[19] F. Tas and K. Erturk, "BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients," Dermatol. Ther., vol. 33, no. 2, 2020, doi: 10.1111/dth.13270.

[20] L. Florent, C. Saby, F. Slimano, and H. Morjani, "BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge," Cancers (Basel)., vol. 15, no. 9, pp. 1–13, 2023, doi: 10.3390/cancers15092607.

[21] N. Using, F. Extract, and C. Toxicity, "Exploring the Biomedical Applications of Biosynthesized Silver," 2023.

[22] N. T. C. Quyen, N. T. N. Quyen, N. N. Quy, and P. M. Quan, "Evaluation of total polyphenol content, total flavonoid content, and antioxidant activity of Centella asiatica," IOP Conf. Ser. Mater. Sci. Eng., vol. 991, no. 1, 2020, doi: 10.1088/1757-899X/991/1/012020.

[23] R. Cohen et al., "BRAF V600EMutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data from the ARCAD Database," J. Natl. Cancer Inst., vol. 113, no. 10, pp. 1386–1395, 2021, doi: 10.1093/jnci/djab042.

[24] J. Tabernero et al., "Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study," J. Clin. Oncol., vol. 39, no. 4, pp. 273–284, 2021, doi: 10.1200/JCO.20.02088.

[25] V. Di Nunno, L. Gatto, A. Tosoni, S. Bartolini, and E. Franceschi, "Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution," Front. Oncol., vol. 12, no. January, pp. 1–12, 2023, doi: 10.3389/fonc.2022.1067252.

[26] S. Imani, G. Roozitalab, M. Emadi, A. Moradi, P. Behzadi, and P. Jabbarzadeh Kaboli, "The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies," Front. Oncol., vol. 14, no. November, pp. 1–25, 2024, doi: 10.3389/fonc.2024.1504142.

[27] P. Hou, D. Liu, J. Dong, and M. Xing, "The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells," Cell Cycle, vol. 11, no. 2, pp. 286–295, 2012, doi: 10.4161/cc.11.2.18707.

[28] J. R. MANULLANG, R. A. NUGROHO, M. ROHMAH, R. RUDIANTO, and A. QORYSUCHI, "Plant-extract-mediated biosynthesis of silver nanoparticles using Eleutherine americana bulb extract and its characterization," Nusant. Biosci., vol. 13, no. 2, pp. 247–254, 2021, doi: 10.13057/nusbiosci/n130216.

[29] P. Kubatka et al., "Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression—3PM pathways," EPMA J., vol. 12, no. 4, pp. 559–587, 2021, doi: 10.1007/s13167-021-00257-y.

[30] H. S. C. Tang and Y. C. Chen, "Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma," Int. J. Nanomedicine, vol. 10, pp. 3131–3146, 2015, doi: 10.2147/IJN.S80150.